000			03678nam a22005415i 4500
001			978-3-642-00663-0
003			DE-He213
005			20140220084522.0
007			cr nn 008mamaa
008			111227s2010 gw | s |||| 0|eng d
020			_a9783642006630 _9978-3-642-00663-0
024	7		_a10.1007/978-3-642-00663-0 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
100	1		_aUetrecht, Jack. _eeditor.
245	1	0	_aAdverse Drug Reactions _h[electronic resource] / _cedited by Jack Uetrecht.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2010.
300			_bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v196
505	0		_aTarget Organ Toxicity -- Drug-Induced Liver Injury -- Drug Hypersensitivity Reactions Involving Skin -- Adverse Drug Reactions Affecting Blood Cells -- Molecular Mechanisms of Adverse Drug Reactions in Cardiac Tissue -- Mechanisms of Drug-Induced Nephrotoxicity -- Receptor- and Reactive Intermediate-Mediated Mechanisms of Teratogenesis -- Mediators/Biochemical Pathways -- Role of Reactive Metabolites in Drug-Induced Hepatotoxicity -- The Role of Cytokines in the Mechanism of Adverse Drug Reactions -- The Keap1-Nrf2 Cellular Defense Pathway: Mechanisms of Regulation and Role in Protection Against Drug-Induced Toxicity -- Signal Transduction Pathways Involved in Drug-Induced Liver Injury -- Mitochondrial Involvement in Drug-Induced Liver Injury -- Examples/Models -- Mechanisms of Acetaminophen-Induced Liver Necrosis -- Drug-Induced Liver Injury in Humans: The Case of Ximelagatran -- Troglitazone -- Nevirapine Hypersensitivity -- Mechanisms of Adverse Drug Reactions to Biologics -- Risk Factors/Screening Drug Candidates -- Pharmacogenetics of Idiosyncratic Adverse Drug Reactions -- The Danger Hypothesis Applied to Idiosyncratic Drug Reactions -- Approaches for Minimizing Metabolic Activation of New Drug Candidates in Drug Discovery.
520			_aThis book provides the current state of knowledge of basic mechanisms of adverse drug reactions (ADRs). The main focus is on idiosyncratic drug reactions because they are the most difficult to deal with. It starts with a general description of the major targets for ADRs followed by a description of what are presently believed to be mediators and biochemical pathways involved in idiosyncratic drug reactions. There is also a description of several examples of ADRs that serve to illustrate specific aspects of ADR mechanisms. Eventually the book shows that ultimately better methods are needed to predict which drug candidates are likely to cause ADRs and which patients are at increased risk. But at present research seems to be far from this goal.
650		0	_aMedicine.
650		0	_aImmunology.
650		0	_aToxicology.
650		0	_aAllergy.
650		0	_aDermatology.
650		0	_aClinical medicine.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aImmunology.
650	2	4	_aPublic Health/Gesundheitswesen.
650	2	4	_aHepatology.
650	2	4	_aDermatology.
650	2	4	_aAllergology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783642006623
830		0	_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v196
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-642-00663-0
912			_aZDB-2-SBL
999			_c111321 _d111321